Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial
Steven A. Lubitz(Icahn School of Medicine at Mount Sinai), Daniel E. Singer(Kaiser Permanente), Ana T. Trisini Lipsanopoulos(Tri-Service General Hospital), Shaan Khurshid(Broad Institute), Jeffrey M. Ashburner(Harvard University), Leila H. Borowsky(Massachusetts General Hospital), Yuchiao Chang(Harvard University), David D. McManus(University of Massachusetts Chan Medical School), Steven J. Atlas(Harvard University), Patrick T. Ellinor(Broad Institute), Wyliena Guan(University of North Carolina at Chapel Hill)
Cited by 119
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Prevalence of Diagnosed Atrial Fibrillation in Adults
|JAMA|2001|6.2k
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
|Nature Genetics|2018|3.1k
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
|Heart Rhythm|2017|2.7k
Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population
|The American Journal of Cardiology|2013|1.3k